JP Morgan Chase
DSGN icon

JP Morgan Chase’s Design Therapeutics DSGN Stock Holding History

JP Morgan Chase’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$147K Sell
14,134
-317
-2% -$3.21K ﹤0.01% 5636
2025
Q4 		$136K Sell
14,451
-8,770
-38% -$68.7K ﹤0.01% 5732
2025
Q3 		$175K Buy
23,221
+4,896
+27% +$24.5K ﹤0.01% 5585
2025
Q2 		$61.8K Sell
18,325
-952
-5% -$3.56K ﹤0.01% 5833
2025
Q1 		$74.4K Sell
19,277
-69,938
-78% -$334K ﹤0.01% 5713
2024
Q4 		$550K Buy
89,215
+48,528
+119% +$281K ﹤0.01% 4984
2024
Q3 		$219K Buy
40,687
+26,503
+187% +$125K ﹤0.01% 5365
2024
Q2 		$47.5K Sell
14,184
-24,520
-63% -$95.5K ﹤0.01% 5881
2024
Q1 		$156K Sell
38,704
-2,556
-6% -$6.83K ﹤0.01% 5474
2023
Q4 		$109K Sell
41,260
-15,082
-27% -$34.5K ﹤0.01% 5695
2023
Q3 		$133K Buy
56,342
+4,359
+8% +$20.3K ﹤0.01% 5320
2023
Q2 		$327K Buy
51,983
+26,027
+100% +$159K ﹤0.01% 4759
2023
Q1 		$150K Buy
25,956
+6,156
+31% +$46K ﹤0.01% 5229
2022
Q4 		$203K Sell
19,800
-73,352
-79% -$994K ﹤0.01% 5031
2022
Q3 		$1.56M Buy
93,152
+74,863
+409% +$1.49M ﹤0.01% 3669
2022
Q2 		$256K Sell
18,289
-1,950
-10% -$26.3K ﹤0.01% 4941
2022
Q1 		$327K Buy
20,239
+4,504
+29% +$69K ﹤0.01% 4939
2021
Q4 		$337K Buy
15,735
+7,598
+93% +$130K ﹤0.01% 5061
2021
Q3 		$120K Buy
8,137
+142
+2% +$2.36K ﹤0.01% 5478
2021
Q2 		$159K Buy
+7,995
New +$202K ﹤0.01% 5345

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase's DSGN Position: Q1 2026 in Review

JP Morgan Chase reduced its Design Therapeutics (DSGN) stake by 2.2% in Q1 2026, selling an estimated $3.21K and leaving 14,134 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #5636.

JP Morgan Chase first reported a position in DSGN in Q2 2021 and has held it in 20 quarters since. The position peaked at $1.56M in Q3 2022. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • JP Morgan Chase held 14,134 shares of Design Therapeutics worth $147K as of Q1 2026.
  • JP Morgan Chase sold 317 Design Therapeutics shares in Q1 2026, an estimated $3.21K.
  • Design Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5636 holding.
  • JP Morgan Chase first reported a position in Design Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • JP Morgan Chase's Design Therapeutics position peaked at $1.56M in Q3 2022.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.